Annette Vangsted

29PUBLICATIONS
145CO-AUTHORS
HaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Mortality
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jun 23, 2026
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

|Oct 08, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero

|Dec 05, 2024
Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.

Tine Rosenberg, Sören Möller, Niels Abildgaard

|Aug 05, 2024
Deciphering the genetics and mechanisms of predisposition to multiple myeloma.

Molly Went, Laura Duran-Lozano, Gisli H Halldorsson

|Apr 15, 2024
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.

Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted

|Mar 12, 2024
Large differencies in age-specific survival in multiple myeloma in the nordic countries.

Kari Hemminki, Frantisek Zitricky, Asta Försti

Pageof 5

Frequent Collaborators

8 joint publications

Fredrik Schjesvold

6 joint publications

Emil Hermansen

5 joint publications

Agoston Gyula Szabo

4 joint publications

Federico Canzian